CN113616646A - 咔啉生物碱在制备抗uvb辐射制剂中的应用 - Google Patents
咔啉生物碱在制备抗uvb辐射制剂中的应用 Download PDFInfo
- Publication number
- CN113616646A CN113616646A CN202111126644.1A CN202111126644A CN113616646A CN 113616646 A CN113616646 A CN 113616646A CN 202111126644 A CN202111126644 A CN 202111126644A CN 113616646 A CN113616646 A CN 113616646A
- Authority
- CN
- China
- Prior art keywords
- carboline
- beta
- pentanone
- trihydroxy
- hydroxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 230000005855 radiation Effects 0.000 title claims abstract description 22
- 229930013930 alkaloid Natural products 0.000 title description 10
- 150000003797 alkaloid derivatives Chemical class 0.000 title description 8
- XKCXIUDPGSNQIQ-UHFFFAOYSA-N 9h-pyrido[3,4-b]indol-1-ylmethanol Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2CO XKCXIUDPGSNQIQ-UHFFFAOYSA-N 0.000 claims abstract description 66
- INDULJXZEHWXFH-UHFFFAOYSA-N 1-hydroxymethyl-beta-carboline Natural products OCC1=NC=CC2C1Nc3ccccc23 INDULJXZEHWXFH-UHFFFAOYSA-N 0.000 claims abstract description 33
- RSEGMZMZRFXVDC-UHFFFAOYSA-N 3,4,5-trihydroxy-1-(9h-pyrido[3,4-b]indol-1-yl)pentan-1-one Chemical compound N1C2=CC=CC=C2C2=C1C(C(=O)CC(O)C(O)CO)=NC=C2 RSEGMZMZRFXVDC-UHFFFAOYSA-N 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 29
- 239000002537 cosmetic Substances 0.000 claims abstract description 20
- 210000005175 epidermal keratinocyte Anatomy 0.000 claims abstract description 19
- 102000004125 Interleukin-1alpha Human genes 0.000 claims abstract description 9
- 108010082786 Interleukin-1alpha Proteins 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 6
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 6
- 230000009759 skin aging Effects 0.000 claims abstract description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 43
- 241001076416 Dendrobium tosaense Species 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 12
- 239000011734 sodium Substances 0.000 description 9
- ZUPHXNBLQCSEIA-UHFFFAOYSA-N 1-methyl-tetrahydro-beta-carboline-3-carboxylic acid Natural products N1C2=CC=CC=C2C2=C1C(C)NC(C(O)=O)C2 ZUPHXNBLQCSEIA-UHFFFAOYSA-N 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- -1 Glycosyl fluorides Chemical class 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- ZUPHXNBLQCSEIA-HQJQHLMTSA-N (1r,3s)-1-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole-3-carboxylic acid Chemical compound N1C2=CC=CC=C2C2=C1[C@@H](C)N[C@H](C(O)=O)C2 ZUPHXNBLQCSEIA-HQJQHLMTSA-N 0.000 description 5
- ZUPHXNBLQCSEIA-CPCISQLKSA-N (1s,3s)-1-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole-3-carboxylic acid Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C)N[C@H](C(O)=O)C2 ZUPHXNBLQCSEIA-CPCISQLKSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241001523681 Dendrobium Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 206010051246 Photodermatosis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 238000006257 total synthesis reaction Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
- BQTUGQOWZZUYIA-UHFFFAOYSA-N 1h-indol-3-yl(9h-pyrido[3,4-b]indol-1-yl)methanone Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C(=O)C1=CNC2=CC=CC=C12 BQTUGQOWZZUYIA-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- NJYJKDXLWUBPOW-UHFFFAOYSA-N [5-(5h-pyrido[4,3-b]indol-1-yl)furan-2-yl]methanol Chemical compound O1C(CO)=CC=C1C1=NC=CC2=C1C1=CC=CC=C1N2 NJYJKDXLWUBPOW-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- UCDVIBNDYLUWFP-UHFFFAOYSA-N glaucocalyxin A Natural products C1C(O)C2(C(C3=C)=O)C(O)C3CCC2C2(C)C1C(C)(C)C(=O)CC2 UCDVIBNDYLUWFP-UHFFFAOYSA-N 0.000 description 2
- UCDVIBNDYLUWFP-MJTHGBBVSA-N glaucocalyxin a Chemical compound C([C@@H]1[C@@H](O)[C@]2(C(C1=C)=O)[C@H](O)C1)C[C@H]2[C@@]2(C)[C@H]1C(C)(C)C(=O)CC2 UCDVIBNDYLUWFP-MJTHGBBVSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- KFUCYPGCMLPUMT-UHFFFAOYSA-N perlolyrine Chemical compound O1C(CO)=CC=C1C1=NC=CC2=C1NC1=CC=CC=C21 KFUCYPGCMLPUMT-UHFFFAOYSA-N 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 241000258957 Asteroidea Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241001573925 Gleba Species 0.000 description 1
- 241000735432 Hydrastis canadensis Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 241000915727 Rhazya stricta Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000973887 Takayama Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
提供1‑(β‑咔啉‑1‑基)‑3,4,5‑三羟基‑1‑戊酮和1‑羟甲基‑β‑咔啉在制备抗UVB辐射的药物制剂中的应用，以及在制备化妆品中的应用。本发明属于医药和化妆品技术领域。1‑(β‑咔啉‑1‑基)‑3,4,5‑三羟基‑1‑戊酮（PFH‑5，0.01~1μg/mL）和1‑羟甲基‑β‑咔啉（PFH‑7，1μg/mL）在非常低的浓度下，既能使UVB辐照后的人表皮角质细胞活性有显著提升，且能显著降低促炎因子IL‑1α的释放，可以用于治疗和预防UVB辐射引起的皮肤衰老、皮肤炎症和皮肤癌变，以及相关药物和化妆品的制备。
Description
技术领域：
本发明属于医药和化妆品技术领域，尤其涉及1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉在制备抗UVB辐射的药物制剂中的应用，以及在制备化妆品中的应用。
背景技术：
人体皮肤接受的日光紫外线辐射主要为UVA(320～400nm)和UVB(280～320nm)，皮肤光老化为UVA和UVB共同作用的结果：一方面，UVA和UVB诱导表皮角质形成细胞和真皮成纤维细胞表达和分泌基质金属蛋白酶(MMPs)，对真皮的细胞外基质发挥降解作用；另一方面，UVA诱导真皮成纤维细胞合成和分泌出细胞因子IL-6，通过自分泌机制促进其自身表达MMPs；更为重要的是，UVB诱导表皮角质形成细胞合成和分泌出细胞因子IL-1、TNF-α、IL-6等，通过旁分泌机制促进真皮成纤维细胞表达MMPs[Nam EJ,Yoo G,Lee JY,Kim M,Jhin C,Son Y-J,Kim SY,Jung SH,Nho CW.Glycosyl flavones from HumulusjaponicussuppressMMP-1production via decreasing oxidative stress in UVB irradiated humandermal fibroblasts.BMB Reports.2020,53,379-384；任倩倩,孙旭,李楠,吴华,金建明.化妆品植物原料(I)——在防晒化妆品中的研究与开发.日用化学工业,2021,51,10-16；王小勇.UVB辐射表皮角质形成细胞和UVA辐射真皮成纤维细胞在皮肤光老化中的作用机理研究.南京医科大学,2006]。此外，UVB辐射还会导致皮肤的炎症和癌症[Takashima A,Bergstresser PR.Impact of UVB radiation on the epidermal cytokinenetwork.Photochemistry and Photobiology,1996,63,397-400]。
据2020版《中华人民共和国药典》记载，兰科植物铁皮石斛Dendrobiumofficinale Kimura et Migo的干燥茎，具有益胃生津、滋阴清热的功能；用于治疗热病津伤、口干烦渴、胃阴不足、食少干呕、病后虚热不退、阴虚火旺、骨蒸劳热、目暗不明、筋骨痿软等病症。铁皮石斛叶，则被作为地方特色食品在利用，如浙江省卫生健康委员会于2020年6月11日发布了浙江省食品安全地方标准《干制铁皮石斛叶》(DB33/3012-2020)(https:// mp.weixin.qq.com/s/-qzRMnAjPF4t1j6Nocuaxg)；贵州省卫生健康委员会于2020年7月17日发布了《铁皮石斛叶(干叶)》食品安全地方标准(http://www.gzhfpc.gov.cn/xwzx_ 500663/zwyw/202007/t20200724_61712723.html)。铁皮石斛叶主要含有多糖、黄酮、联苄、甾体等类型化学成分[Wang Y-H.Traditional uses,chemical constituents,pharmacological activities,and toxicological effects of Dendrobium leaves:Areview.Journal of Ethnopharmacology,2021,270,113851；张春花,徐巧林,曾雷,王颂,罗青文,陈颖乐.铁皮石斛叶的化学成分研究.林业与环境科学,2020,36(3),30-34；唐靖雯,卢礼平,王欢,梁斌,潘梅.铁皮石斛叶的研究进展.中国民族民间医药,2020,29(7),63-67；任刚,陈优婷,叶金宝,钟国跃,肖川云,邓文赞,陈云龙.铁皮石斛叶的化学成分研究.中草药,2020,51(14),3637-3644；Ren G.,Deng W.-Z.,Xie Y.-F.,Wu C.-H.,Li W.-Y.,XiaoC.-Y.,Chen Y.-L.Bibenzyl derivatives from leaves of Dendrobiumofficinale.Natural Product Communications,2020,15(2),1-5]。
此前的专利申请公开了铁皮石斛叶中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉等生物碱的制备方法[王跃虎,张东东,罗吉凤.铁皮石斛叶生物碱的制备方法及其应用.2020.12.13,中国专利,202011453693.1]，但是，1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉在抗UVB辐射方面的作用，尚未见到报道。
发明内容：
针对现有技术存在的1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉研发中的空白，发明人对铁皮石斛叶中的生物碱抗UVB的活性进行了评价，1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉表现出显著的活性，可以用于制备抗UVB的药物和化妆品。
为了实现本发明的上述目的，本发明提供了如下的技术方案：
1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉在制备抗UVB辐射药物制剂中的应用。
1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉在制备抗UVB辐射化妆品中的应用。
如所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮的用量为0.01～1μg/mL，1-羟甲基-β-咔啉的用量为1μg/mL。
如所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉通过使UVB辐照后的人表皮角质细胞活性显著提升达到抗UVB辐照的活性作用。
如所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉通过显著降低促炎因子IL-1α的释放达到抗UVB辐照的活性作用。
1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉在制备治疗或预防UVB辐射引起的皮肤老化、皮肤炎症和皮肤癌的药物中的应用。
如所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮的用量为0.01～1μg/mL，1-羟甲基-β-咔啉的用量为1μg/mL。
如所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉通过使UVB辐照后的人表皮角质细胞活性显著提升达到抗UVB辐照的活性作用。
如所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉通过显著降低促炎因子IL-1α的释放达到治疗皮肤老化、皮肤炎症和皮肤癌的作用。
化妆品，其由1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉其中之一或两者加合，以及化妆品常用辅料所组成。
与现有相关技术相比，本发明具备如下的优益性：
1. 1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮(0.01～1μg/mL)和1-羟甲基-β-咔啉(1μg/mL)在非常低的浓度即可发挥其对UVB辐射的保护作用。
2. 1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉既能使UVB辐照后的人表皮角质细胞活性有显著提升，且能显著降低促炎因子IL-1α的释放。
3. 1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉对人表皮角质细胞没有毒性。
4. 1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉能用于治疗或预防皮肤病、炎症疾病、肿瘤疾病。
附图说明：
图1为本发明铁皮石斛叶生物碱成分的化学结构式。
图2为PFH-2的晶体结构。
图3为PFH-5的晶体结构。
具体实施方式：
下面结合附图，用本发明的实施例来进一步说明本发明的实质性内容，但并不以此来限定本发明。
实施例1：
铁皮石斛叶中生物碱成分(1S,3S)-1-甲基-1,2,3,4-四氢-β-咔啉-3-羧酸[(1S,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid,PFG-5]、(1R,3S)-1-甲基-1,2,3,4-四氢-β-咔啉-3-羧酸[(1R,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid,PFG-6a]、川芎哚(perlolyrine,PFH-1)、β-咔啉(β-carboline,PFH-2)、1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮[1-(β-carbolin-1-yl)-3,4,5-trihydroxy-1-pentanone,PFH-5]和1-羟甲基-β-咔啉(1-hydroxymethyl-β-carboline,PFH-7)的提取、分离：
铁皮石斛叶9.0kg，90～95％乙醇提取，回收溶剂，得到粗提物(浸膏)2.3kg。粗提物加入1L水制备成混悬液，加入3L石油醚萃取，重复8次；萃取后的水相用6M盐酸调节pH值为2～3，用3L乙酸乙酯萃取，重复5次；萃取后的水相用50％氢氧化钠水溶液调节pH值为9～10，用2L二氯甲烷萃取，重复5次；萃取后的水相用6M盐酸调节pH值至7左右，用2L正丁醇萃取，重复5次。回收溶剂后，分别得到石油醚萃取部位520.0g，乙酸乙酯萃取部位156.0g，二氯甲烷萃取部位(铁皮石斛叶的二氯甲烷萃取总生物碱部位)5.9g，以及正丁醇萃取部位85.6g。
二氯甲烷萃取部位经硅胶柱层析用石油醚-丙酮(5:1，3:1，1:1)，二氯甲烷-甲醇(1:1)，以及甲醇洗脱，得到Fr.A、Fr.B、Fr.C、Fr.D、Fr.E、Fr.F和Fr.G等七个部分。
(1)Fr.B(石油醚-丙酮5:1洗脱部分，815.5mg)经C18反相硅胶柱层析，甲醇-水(30:70→100:0)梯度洗脱，得到Fr.B1、Fr.B2、Fr.B3、Fr.B4和Fr.B5等五个部分。
(2)Fr.B2(30～50％甲醇洗脱部分)经LH-20凝胶柱层析用甲醇洗脱，用半制备高效液相色谱纯化得到PFH-1(23.4mg)和PFH-2(3.8mg)。
(3)Fr.C(石油醚-丙酮3:1洗脱部分，502.9mg)经C18反相硅胶柱层析，甲醇-水(10:90→100:0)梯度洗脱，得到Fr.C1、Fr.C2、Fr.C3、Fr.C4、Fr.C5和Fr.C6等六个部分。Fr.C3(20～30％甲醇洗脱部分)用半制备高效液相色谱纯化后得到PFH-7(1.9mg)。
(4)Fr.D(石油醚-丙酮1:1洗脱部分，223.3mg)经C18反相硅胶柱层析，甲醇-水(5:95→100:0)梯度洗脱，得到Fr.D1、Fr.D2、Fr.D3、Fr.D4、Fr.D5和Fr.D6等六个部分。Fr.D4(30～40％甲醇洗脱部分)用半制备高效液相色谱纯化得到PFH-5(15.4mg)。
正丁醇萃取部位经硅胶柱层析，用二氯甲烷-甲醇(20:1→1:1)，以及甲醇洗脱，得到Fr.H、Fr.I、Fr.J、Fr.K、Fr.L和Fr.M等六个部分。Fr.K(二氯甲烷-甲醇3:1洗脱部分，30.4g)经RP C18反相硅胶柱层析，甲醇-水(5:95→100:0)梯度洗脱，得到Fr.K1、Fr.K2、Fr.K3、Fr.K4、Fr.K5、Fr.K6和Fr.K7等七个部分。Fr.K4(10％甲醇洗脱部分，559.5mg)经LH-20凝胶柱层析用甲醇洗脱后，再用半制备高效液相色谱纯化得到PFG-5(3.5mg)和PFG-6a(2.5mg)。
上面所述的半制备高效液相色谱使用的仪器是安捷伦1260Infinity II液相色谱仪。
制备PFH-1和PFH-2所用色谱柱为Agilent Zorbax SB-C18柱，大小为9.4×250mm，洗脱剂为甲醇-水(比例60:40)，流速2mL/min，保留时间分别为25.600min和21.260min。
制备PFH-7所用色谱柱为Agilent Zorbax SB-C18柱，大小为9.4×250mm，洗脱剂为乙腈-水(30:70)，流速2mL/min，保留时间为17.070min。
制备PFH-5所用色谱柱为Agilent Zorbax SB-C18柱，色谱柱大小为9.4×250mm，洗脱剂为甲醇-水(55:45)，流速2mL/min，保留时间为14.513min。
制备PFG-5所用色谱柱为Agilent Zorbax SB-Aq柱，大小为4.6×250mm，洗脱剂为甲醇-水(比例5:95)，流速1mL/min，保留时间为16.800min。
制备PFG-6a所用色谱柱为Agilent Zorbax SB-Aq柱，大小为4.6×250mm，洗脱剂为甲醇-水(比例3:97)，流速1mL/min，保留时间为30.572min。
实施例2：
铁皮石斛叶生物碱成分的波谱数据：
(1S,3S)-1-甲基-1,2,3,4-四氢-β-咔啉-3-羧酸[(1S,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid，PFG-5]，浅黄色固体，分子式C13H14N2O2，CAS登记号40678-46-4。[α]24 D-100(c 0.13,MeOH)。1H NMR(methanol-d4,500MHz)δ:7.48(1H,brd,J＝7.9Hz,H-5),7.34(1H,br d,J＝8.1Hz,H-8),7.14(1H,m,H-7),7.05(1H,m,H-6),4.71(1H,q,J＝6.3Hz,H-1),3.97(1H,dd,J＝12.0,4.9Hz,H-3),3.45(1H,dd,J＝16.5,4.9Hz,H-4α),3.03(1H,m,H-4β),1.75(3H,d,J＝6.7Hz,1-Me)。13C NMR(methanol-d4,126MHz,)δ:173.7(C,3-COOH,detected by HMBC),138.6(C,C-8a),131.4(C,C-9a),127.5(C,C-4b),123.3(CH,C-7),120.6(CH,C-6),119.2(CH,C-5),112.3(CH,C-8),107.9(C,C-4a),59.8(CH,C-3),51.2(CH,C-1),24.3(CH2,C-4),17.2(CH3,1-Me)。ESI-MS m/z 253[M+Na]+。其核磁共振波谱数据跟文献[Alla A.Kicha,Natalia V.Ivanchina,Anatoly I.Kalinovsky,Pavel S.Dmitrenok,Valentin A.Stonik.Alkaloidosteroids from the starfish Lethasteriasnanimensischelifera.Tetrahedron Letters,2003,44(9),1935–1937]中的数据基本一致。
(1R,3S)-1-甲基-1,2,3,4-四氢-β-咔啉-3-羧酸[(1R,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid,PFG-6a]，浅黄色固体，分子式C12H14N2O，CAS登记号42438-72-2。[α]28 D-11(c 0.09,MeOH)。1H NMR(methanol-d4,500MHz)δ:7.46(1H,brd,J＝7.9Hz,H-5),7.31(1H,br d,J＝8.1Hz,H-8),7.12(1H,m,H-7),7.03(1H,m,H-6),4.83(1H,q,J＝6.7Hz,H-1),4.07(1H,dd,J＝8.7,5.6Hz,H-3),3.34(1H,dd,J＝16.2,5.6Hz,H-4α),3.13(1H,dd,J＝16.2,8.7Hz,H-4β),1.69(1H,d,J＝6.9Hz,1-Me)。13C NMR(methanol-d4,126MHz,)δ:138.4(C,C-8a),130.9(C,C-9a),127.6(C,C-4b),123.2(CH,C-7),120.4(CH,C-6),119.1(CH,C-5),112.1(CH,C-8),106.7(C,C-4a),54.8(CH,C-3),48.5(CH,C-1),24.1(CH2,C-4),18.8(CH3,1-Me)。ESI-MS m/z 231[M+H]+,253[M+Na]+,483[2M+Na]+。其核磁共振波谱数据跟文献[Wang X,Liu R,Yang Y,Zhang M.Isolation,purification andidentification of antioxidants in an aqueous aged garlic extract.FoodChemistry,2015,187,37-43]中的数据基本一致。
川芎哚(perlolyrine,PFH-1)，浅黄色针状晶体(甲醇)，分子式C16H12N2O2，CAS登记号29700-20-7。1H NMR(pyridine-d5,500MHz)δ:12.06(1H,s,NH),8.67(1H,d,J＝5.1Hz,H-3),8.26(1H,d,J＝8.0Hz,H-5),8.03(1H,d,J＝5.1Hz,H-4),7.57(1H,overlapped,H-8),7.51(1H,m,H-7),7.31(1H,m,H-6),7.19(1H,overlapped,H-2′),6.67(1H,br d,J＝3.3Hz,H-3′),4.70(2H,s,H-5′)。13C NMR(pyridine-d5,126MHz)δ:157.7(C,C-1′),154.2(C,C-4′),141.9(C,C-8a),138.9(CH,C-3),134.5(C,C-1),131.8(C,C-9a),130.4(C,C-4a),128.5(CH,C-7),121.8(CH,C-5),121.7(C,C-4b),120.0(CH,C-6),113.7(CH,C-4),112.6(CH,C-8),110.1(CH,C-2′),109.4(CH,C-3′),57.0(CH2,C-5′)。ESIMS m/z 287[M+Na]+,551[2M+Na]+。其核磁共振波谱数据跟文献[Dassonneville,B.；Witulski,B.；Detert,H.[2+2+2]Cycloadditions of alkynylynamides–A total synthesis of perlolyrine and thefirst total synthesis of“isoperlolyrine”.European Journal of OrganicChemistry,2011,2011(15),2836-2844]中的数据一致。
PFH-1的晶体数据:C16H12N2O2·CH4O,M＝296.32,
α＝90°,β＝90°,γ＝90°,
T＝100.(2)K,space group Fdd2,Z＝16,μ(Cu Kα)＝0.783mm-1,22212reflections measured,2822independent reflections(Rint＝0.0306).The final R1 values were0.0273(I>2σ(I)).The final wR(F2)values were 0.0727(I>2σ(I)).The final R1 values were0.0274(all data).The final wR(F2)values were 0.0729(all data).The goodness offit on F2 was 1.082.Flack parameter＝-0.03(4).
β-咔啉(β-carboline,PFH-2)，白色固体，分子式C11H8N2，CAS登记号244-63-3。1HNMR(methanol-d4,600MHz)δ:8.80(1H,s,H-1),8.29(1H,d,J＝5.1Hz,H-3),8.19(1H,br d,J＝8.1Hz,H-5),8.10(1H,d,J＝5.1Hz,H-4),7.57(2H,m,H-7,H-8),7.27(1H,m,H-6)。13CNMR(methanol-d4,151MHz,)δ:142.8(C,C-8a),138.4(CH,C-3),137.8(C,C-9a),134.1(CH,C-1),130.5(C,C-4a),129.8(CH,C-7),122.7(CH,C-5),122.2(C,C-4b),120.9(CH,C-6),116.1(CH,C-4),112.8(CH,C-8)。ESIMS m/z 169[M+H]+。其核磁共振波谱数据跟文献[杨泊涛；刘录；张敉；刘亚平；李宝才；秦徐杰.景东山橙根中生物碱成分研究.天然产物研究与开发,2016,28(6),868-873,954]中的数据一致。
1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮[1-(β-carbolin-1-yl)-3,4,5-trihydroxy-1-pentanone,PFH-5]，浅黄色片状结晶(甲醇)，分子式C16H16N2O4，CAS登记号180995-40-8。[α]25 D–14(c 0.3,MeOH)。ECD(c0.024,MeOH)λmax(Δε)225(+1.59),201(-2.72)nm。1H NMR(methanol-d4,500MHz)δ:8.46(1H,d,J＝5.0Hz,H-3),8.29(1H,d,J＝5.0Hz,H-4),8.21(1H,brd,J＝7.9Hz,H-5),7.70(1H,brd,J＝8.2Hz,H-8),7.59(1H,m,H-7),7.31(1H,m,H-6),4.35(1H,m,H-3′),3.83(1H,m,H-5′a),3.60-3.69(4H,m,H2-2′,H-4′,H-5′b)。13C NMR(methanol-d4,126MHz)δ:203.6(C,C-1′),143.4(C,C-8a),138.5(CH,C-3),137.3(C,C-1),136.3(C,C-9a),133.3(C,C-4a),130.3(CH,C-7),122.7(CH,C-5),121.6(C,C-4b),121.6(CH,C-6),120.1(CH,C-4),113.4(CH,C-8),76.2(CH,C-4′),70.3(CH,C-3′),64.7(CH2,C-5′),43.1(CH2,C-2′)。ESIMS m/z 323[M+Na]+,623[2M+Na]+。其核磁共振波谱数据跟文献[Aimi,N.；Kitajima,M.；Oya,N.；Nitta,W.；Takayama,H.；Sakai,S.-i.；Kostenyuk,I.；Gleba,Y.；Endreb,S.；
J.Isolation of alkaloids fromcultured hybrid cells ofRauwolfiaserpentina×Rhazyastricta.Chemical andPharmaceutical Bulletin,1996,44(8),1637-1639]中的数据一致。
PFH-5的晶体数据:C16H16N2O4,M＝300.31,
α＝94.7500(10)°,β＝93.7600(10)°,γ＝99.7690(10)°,
T＝100.(2)K,space group P1,Z＝1,μ(Cu Kα)＝0.874mm-1,8649reflections measured,2568independent reflections(Rint＝0.0311).The finalR1 values were 0.0299(I>2σ(I)).The final wR(F2)values were 0.0833(I>2σ(I)).Thefinal R1values were 0.0299(all data).The final wR(F2)values were 0.0833(alldata).The goodness of fit on F2 was 1.176.Flack parameter＝0.05(5).
1-羟甲基-β-咔啉(1-hydroxymethyl-β-carboline,PFH-7)，浅黄色固体，分子式C12H10N2O，CAS登记号17337-22-3。1H NMR(pyridine-d5,600MHz)δ:12.43(1H,s,NH),8.60(1H,d,J＝5.2Hz,H-3),8.29(1H,d,J＝8.0Hz,H-5),8.06(1H,d,J＝5.2Hz,H-4),7.72(1H,d,J＝8.0Hz,H-8),7.58(1H,m,H-7),7.33(1H,m,H-6),5.54(2H,s,H2-1′)。13C NMR(pyridine-d5,151MHz)δ:146.6(C,C-1),142.2(C,C-8a),138.4(CH,C-3),135.3(C-9a),129.7(C,C-4a),128.9(CH,C-7),122.5(CH,C-5),122.4(C,C-4b),120.2(CH,C-6),114.5(CH,C-4),112.9(CH,C-8),65.6(CH2,C-1′)。ESIMS m/z 199[M+H]+,221[M+Na]+,419[2M+Na]+。该化合物的结构得到二维核磁共振波谱和单晶X射线衍射的确认。其核磁共振波谱数据跟文献[Szabó,T.；Hazai,V.；Volk,B.；Simig,G.；Milen,M.First total synthesis oftheβ-carboline alkaloids trigonostemine A,trigonostemine B and a newsynthesis of pityriacitrin and hyrtiosulawesine.Tetrahedron Letters,2019,60(22),1471-1475]中用DMSO-d6测试的数据接近。
实施例3：
咔啉类化合物对人原代表皮角质细胞活力实验。
人原代表皮角质细胞在37℃、5％CO2、饱和湿度的培养条件下，利用专用的角质细胞培养基正常培养。细胞生长达到80％汇合时进行消化，细胞悬液密度调整至1×105个/mL，以每孔200μL细胞悬液接种于96孔板中，贴壁48h后，加入5个浓度梯度(10μg/mL、1μg/mL、0.5μg/mL、0.1μg/mL、0.01μg/mL)的样品处理角质细胞，同时设置溶剂对照组(Vehicle)，即含有0.1％DMSO的角质细胞培养基。
处理角质细胞24h后测试其活性，按照说明书加入CCK-8试剂孵育1h，在450nm处测量吸光度，计算相对细胞活性。
相对细胞活性％＝(样品组OD值/溶剂对照组OD值)×100％。
实验结果见表1。从表1可以看出，除化合物PFH-1在浓度10μg/mL时，对表皮角质细胞有弱的抑制作用外，其余化合物在10μg/mL、1μg/mL、0.5μg/mL、0.1μg/mL、0.01μg/mL五个浓度下，均对表皮角质细胞没有抑制作用。说明咔啉类化合物PFG-5、PFG-6a、PFH-1、PFH-2、PFH-5和PFH-7在本实验所设置的浓度下，对表皮角质细胞几乎没有毒性。
表1.咔啉类化合物的表皮角质细胞活性测试数据
实施例3：
咔啉类化合物对UVB辐射人原代表皮角质细胞的活力影响和IL-1α生成量测定：
在含5％CO2、37℃、饱和湿度的培养条件下，利用Promocell完全培养基正常培养人原代表皮角质细胞。选取处于最佳生长状态的细胞，将其按照1×105个/mL、每孔200μL的密度接种于96孔板中，贴壁生长48h后，先用UVB10mJ/cm2辐照细胞，随后用安全浓度下的样品处理细胞，同时设置溶剂对照组(0.1％DMSO)和抗炎阳性对照组，即1μM蓝萼甲素(Glaucocalyxin A，GLA)[周鲁先,李宁,王惠琇.蓝萼甲素在制备消炎和抗光老化产品中的应用.2021.05.11,中国专利,ZL201910119443.5.]。继续培养24h后，收集细胞上清液用IL-1αELISA试剂盒进行炎症因子检测。同步平行用CCK法检测本实验中各组细胞的活性，IL-1α定量检测结果用CCK所测得的细胞活性进行归一化处理。
实验结果见表2。化合物PFH-5和PFH-7对UVB辐照后的人表皮角质细胞活性有显著提升，且能显著降低炎症因子IL-1α的释放。化合物PFG-5、PFH-1和PFH-2对UVB辐照后的人表皮角质细胞活性有显著提升作用。
表2.UVB辐照的人原代表皮角质细胞活性和IL-1α测试数据
实施例4
β-咔啉(β-carboline,PFH-2)、1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮[1-(β-carbolin-1-yl)-3,4,5-trihydroxy-1-pentanone,PFH-5]的药物制剂：
1.片剂：将PFH-2或/和PFH-5 10mg，加入乳糖180mg，淀粉55mg等辅料混合均匀，并用水将其润湿后制成颗粒并干燥，再加入硬脂酸镁5mg混匀后压片，每片约重250mg。
2.安瓿剂：将PFH-2或/和PFH-52mg，氯化钠10mg，溶解于适量的注射用水中，过滤所得溶液，在无菌条件下装入安瓿瓶中。
3.注射用冻干剂：将PFH-2或/和PFH-5 10mg，碳酸氢钠2mg，甘露醇252mg。
制备方法：将碳酸氢钠、甘露醇，加注射用水溶解，加活性碳吸附30min除热原，过滤除去活性碳，在滤液中加入化合物或其盐，超声处理使溶解，用1N盐酸调节PH为5.0-7.0，微孔滤膜滤过，加注射用水，分装，冷冻干燥，上塞，轧盖，即得。
4.胶囊剂：将PFH-2或/和PFH-5 10mg，乳糖187mg，硬脂酸镁3mg；制备方法：将化合物或其盐与助溶剂混和，过筛，均匀混合，把得到的混合物装入硬明胶胶囊，每个胶囊重200mg，活性成分含量为10mg。
实施例5
β-咔啉(β-carboline,PFH-2)、1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮[1-(β-carbolin-1-yl)-3,4,5-trihydroxy-1-pentanone,PFH-5]的化妆品制剂：
1.含有PFH-2或/和PFH-5的美白霜配方(W％)：
按常规制作化妆品的方法制得本发明上述配方的化妆品。
2.含有PFH-2或/和PFH-5的乳剂配方(W％)：
按常规制作化妆品的方法制得本发明上述配方的化妆品。
Claims (10)
1.1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉在制备抗UVB辐射药物制剂中的应用。
2.1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉在制备抗UVB辐射化妆品中的应用。
3.如权利要求1或2所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮的用量为0.01~1μg/mL，1-羟甲基-β-咔啉的用量为1μg/mL。
4.如权利要求1或2所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉通过使UVB辐照后的人表皮角质细胞活性显著提升达到抗UVB辐照的活性作用。
5.如权利要求1或2所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉通过显著降低促炎因子IL-1α的释放达到抗UVB辐照的活性作用。
6.1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉在制备治疗或预防UVB辐射引起的皮肤老化、皮肤炎症和皮肤癌的药物中的应用。
7.如权利要求6所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮的用量为0.01~1μg/mL，1-羟甲基-β-咔啉的用量为1μg/mL。
8.如权利要求6所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉通过使UVB辐照后的人表皮角质细胞活性显著提升达到抗UVB辐照的活性作用。
9.如权利要求6所述的应用，其中1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮或/和1-羟甲基-β-咔啉通过显著降低促炎因子IL-1α的释放达到治疗皮肤老化、皮肤炎症和皮肤癌的作用。
10.化妆品，其由1-(β-咔啉-1-基)-3,4,5-三羟基-1-戊酮和1-羟甲基-β-咔啉其中之一或两者加合，以及化妆品常用辅料所组成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111126644.1A CN113616646B (zh) | 2021-09-26 | 2021-09-26 | 咔啉生物碱在制备抗uvb辐射制剂中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111126644.1A CN113616646B (zh) | 2021-09-26 | 2021-09-26 | 咔啉生物碱在制备抗uvb辐射制剂中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113616646A true CN113616646A (zh) | 2021-11-09 |
| CN113616646B CN113616646B (zh) | 2024-04-02 |
Family
ID=78390591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111126644.1A Active CN113616646B (zh) | 2021-09-26 | 2021-09-26 | 咔啉生物碱在制备抗uvb辐射制剂中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113616646B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110094572A (ko) * | 2010-02-17 | 2011-08-24 | 부산대학교 산학협력단 | 베타-카르볼린 알칼로이드를 함유하는 멜라닌 생성 촉진용 조성물 |
| WO2018186724A1 (ko) * | 2017-04-07 | 2018-10-11 | 한국 한의학 연구원 | 꽃벵이 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 피부 보습 또는 피부 주름 개선용 조성물 |
| CN112457261A (zh) * | 2020-12-12 | 2021-03-09 | 中国科学院昆明植物研究所 | 铁皮石斛叶生物碱的制备方法及其应用 |
| CN113166152A (zh) * | 2018-06-15 | 2021-07-23 | 弗西科勒技术有限责任公司 | 含有马拉色氏霉菌属（malassezia）衍生的化合物和/或其化学类似物的光防护性组合物 |
-
2021
- 2021-09-26 CN CN202111126644.1A patent/CN113616646B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110094572A (ko) * | 2010-02-17 | 2011-08-24 | 부산대학교 산학협력단 | 베타-카르볼린 알칼로이드를 함유하는 멜라닌 생성 촉진용 조성물 |
| WO2018186724A1 (ko) * | 2017-04-07 | 2018-10-11 | 한국 한의학 연구원 | 꽃벵이 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 피부 보습 또는 피부 주름 개선용 조성물 |
| CN113166152A (zh) * | 2018-06-15 | 2021-07-23 | 弗西科勒技术有限责任公司 | 含有马拉色氏霉菌属（malassezia）衍生的化合物和/或其化学类似物的光防护性组合物 |
| CN112457261A (zh) * | 2020-12-12 | 2021-03-09 | 中国科学院昆明植物研究所 | 铁皮石斛叶生物碱的制备方法及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113616646B (zh) | 2024-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1506951B1 (en) | Method for the preparation of total salvianolic acid | |
| CN108610387B (zh) | 一种具有神经细胞保护活性的四个异黄烷苷类化合物及其制备方法 | |
| US20040067263A1 (en) | Method for preparating an anemone raddeana extract and the pharmaceutical composition containing the same as well as use thereof | |
| CN107137438B (zh) | 腊梅属植物抗结核杆菌的用途 | |
| JP2014097977A (ja) | Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物 | |
| CN113616646B (zh) | 咔啉生物碱在制备抗uvb辐射制剂中的应用 | |
| CN109276637B (zh) | 韭菜子提取物及其制备方法和在制备保肝护肝药物方面的应用 | |
| CN108250167B (zh) | 基于紫外诱导的桑叶中生物活性单体成分chalcomoracin及其制备方法和用途 | |
| CN105777839B (zh) | 一种抗肿瘤化合物、其提取方法及其应用 | |
| CN110204477B (zh) | 一种具有抗氧化作用的二萜生物碱及其在制备药物中的应用 | |
| CN115040503B (zh) | 螺环二烯酮型木脂素类化合物在制药中的应用 | |
| CN113425725B (zh) | 盖裂果及其提取物在制备抗幽门螺杆菌药物中的应用 | |
| JP7393457B2 (ja) | フランアスピドスペルミン二量体又はその薬学的に許容される塩及びその製造方法と適用、ならびに医薬組成物 | |
| CN114507265B (zh) | 一种植物药百两金中的新单萜苷化合物及其提取分离方法和应用 | |
| JP6441526B2 (ja) | Ｔｉｅ２活性化剤、血管の成熟化剤、及び血管の安定化剤、並びにＴｉｅ２活性化用経口組成物 | |
| CN115073463B (zh) | 一类苦参碱型二聚体生物碱类化合物、其药物组合物及其应用 | |
| BG66818B1 (bg) | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки | |
| CN111690023B (zh) | 马钱苷乙酰化衍生物类环烯醚萜化合物及其提取方法和应用 | |
| CN101565444B (zh) | 鹧鸪麻中环阿尔廷型三萜及制备方法和用途 | |
| KR101201866B1 (ko) | 고미신-ａ를 유효성분으로 함유하는 암 예방 및 치료를 위한 약학 조성물 | |
| CN113185528A (zh) | 选择性抗破骨细胞生物碱14-hydroxygelsenicine的药物应用 | |
| CN113773354A (zh) | 大花独蒜兰丁二酸类化合物及其提取方法和应用 | |
| CN103641883A (zh) | 枸骨皂苷化合物的制备方法及应用 | |
| JP2019023238A (ja) | Ｔｉｅ２活性化剤、血管の成熟化剤、及び血管の安定化剤、並びにＴｉｅ２活性化用経口組成物 | |
| CN116265455A (zh) | 一类倍半萜-生物碱杂聚体及其制备方法和制药的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |